announcement

Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them

Company announcement no. 7/2025 In accordance with Article 19 (3) of the Market Abuse Regulation, Columbus A/S is required to…

4 weeks ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

1 month ago

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…

1 month ago
Show previous Posts